logo

For the Inventor, By the Inventor

Groton, CT, United States of America

Pfizer Products Inc.


USPTO Granted Patents = 47

% Expired Patents = 78.7



Forward Citations = 450

Loading Chart...
Loading Chart...

121 inventors (with patents filed for the assignee):

goldMedal Laura Cook Blumberg (5 out of 51 patents)

silverMedal Michael John Munchhof (5 out of 53 patents)

bronzeMedal Douglas James Critcher (4 out of 9 patents)

4.  Mohamad A Morsey (3 out of 40 patents)

5.  Kim Jonelle Stutzman-Engwall (3 out of 15 patents)

6.  Yan Chen (2 out of 88 patents)

7.  Seiji Nukui (2 out of 23 patents)

8.  Anthony Marfat (2 out of 62 patents)

9.  Hui Li (2 out of 15 patents)

10.  Chunfeng Yin (2 out of 10 patents)

11.  Yufeng Hong (2 out of 25 patents)

12.  Anke Krebber (2 out of 21 patents)

13.  Claes Gustafsson (2 out of 44 patents)

14.  Kevin Kun-Chin Liu (2 out of 4 patents)

15.  Iriny Botrous (2 out of 8 patents)


Core Competencies:
Antimicrobial Preservatives
Beta-Cyclodextrins
Pyrimidine Derivatives
TGF Inhibitors
Peptide Vaccines
PDE4 Isozymes
Opioid Receptor Ligands
Glucocorticoid Receptor Modulators
Thyroid Receptor Ligands
Parasiticides
Hybrid Virus Vaccines
Drug Delivery Systems

47 patents:

1. 8999981 - [object Object] (2015-04-07),
2. 8183230 - Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms (2012-05-22),
3. 8114871 - 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives (2012-02-14),
4. 8008078 - [object Object] (2011-08-30),
5. 7968584 - Substituted arylpyrazoles (2011-06-28),
6. 7858340 - [object Object] (2010-12-28),
7. 7820648 - Pyrimidine derivatives for the treatment of abnormal cell growth (2010-10-26),
8. 7803832 - N-(1-arylpyrazol-4L)sulfonamides and their use as parasiticides (2010-09-28),
9. 7687533 - N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides (2010-03-30),
10. 7687507 - Pyrrolo[2,3-d]pyrimidine compounds (2010-03-30),
11. 7638537 - Pyrazole compounds as transforming growth factor (TGF) inhibitors (2009-12-29),
12. 7635702 - Imidazole compounds as transforming growth factor (TGF) inhibitors (2009-12-22),
13. 7538134 - Substituted arylpyrazoles (2009-05-26),
14. 7420047 - Non-anaphylactogenic IgE fusion proteins (2008-09-02),
15. 7417041 - Imidazopyrimidines as transforming growth factor (TGF) inhibitors (2008-08-26),
Company Overview
Pfizer Products Inc., headquartered in Groton, Connecticut, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative healthcare solutions. The company specializes in a diverse range of therapeutic areas, including antimicrobial preservatives, beta-cyclodextrins, and various derivatives such as pyrimidine and cannabinoid receptor ligands. Pfizer is committed to advancing medical science through research in non-anaphylactogenic IgE fusion proteins, PPAR activators, and transforming growth factor inhibitors, contributing significantly to global health advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Pfizer Products Inc. USPTO Patent Assignee Logo
47 Patents

#2 in Groton, CT

#195 in Connecticut

#7,437 in US

#14,821 in the World

Groton, CT (US)
Groton, CT, United States of America

Pfizer Products Inc.

Forward Citations = 450

121 inventors:

goldMedal Laura Cook Blumberg (5 out of 51 patents)

silverMedal Michael John Munchhof (5 out of 53 patents)

bronzeMedal Douglas James Critcher (4 out of 9 patents)

4.  Mohamad A Morsey (3 out of 40 patents)

5.  Kim Jonelle Stutzman-Engwall (3 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pfizer Products Inc.. Retrieved from https://idiyas.com/company/pfizer-products

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…